Systemic sclerosis: The heart of the matter

Hellenic Journal of Cardiology

Volumn 53, Issue 4, 2012, Pages 287-300

  Plastiras, Sotiris C ^a,b   Toumanidis, Savvas T ^a  

^a ALEXANDRA HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Heart involvement; Systemic sclerosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; COLLAGEN; CORTICOSTEROID; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FLUORODEOXYGLUCOSE F 18; IMMUNOSUPPRESSIVE AGENT; NICARDIPINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; THALLIUM 201; VASODILATOR AGENT; VERAPAMIL;

ARTIFICIAL HEART PACEMAKER; AUTOPSY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC DISEASE; COLD PRESSOR TEST; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DEFIBRILLATOR; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DOPPLER ECHOCARDIOGRAPHY; DRUG CONTRAINDICATION; DRUG UPTAKE; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMODYNAMIC PARAMETERS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LUNG FIBROSIS; MICROVASCULATURE; MORBIDITY; MORTALITY; MYOCARDITIS; PATHOPHYSIOLOGY; PERICARDIAL DISEASE; PERICARDIAL EFFUSION; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; RADIOFREQUENCY ABLATION; RAYNAUD PHENOMENON; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL; SYSTEMIC SCLEROSIS; TISSUE DOPPLER IMAGING; TREATMENT INDICATION;

ENDOMYOCARDIAL FIBROSIS; HEART DISEASES; HUMANS; PREVALENCE; SCLERODERMA, SYSTEMIC;

EID: 84864673371     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Steen V. The heart in systemic sclerosis. Curr Rheumatol Rep. 2004; 6: 137-140.
2. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005; 118: 2-10.
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007; 66: 940-944.
4. Allanore Y, Meune C, Kahan A. Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol. 2008; 20: 697-702.
5. Ferri C, Giuggioli D, Sebastiani M, Colaci M, Emdin M. Heart involvement and systemic sclerosis. Lupus. 2005; 14: 702-707.
6. Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford). 2006; 45 Suppl 4: iv14-iv17.
7. Steen VD, Medsger TA. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000; 133: 600-603.
8. Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000; 43: 2437-2444.
9. Vlachoyiannopoulos PG, Dafni UG, Pakas I, Spyropoulou-Vlachou M, Stavropoulos-Giokas C, Moutsopoulos HM. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis. 2000; 59: 359-367.
10. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002; 81: 139-153.
11. Follansbee WP, Curtiss EI, Medsger TA, et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med. 1984; 310: 142-148.
12. Tzelepis GE, Kelekis NL, Plastiras SC, et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum. 2007; 56: 3827-3836.
13. Furst DE, Clements PJ, Hillis S, et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum. 1989; 32: 584-593.
14. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore). 2002; 81: 154-67.
15. Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation. 1976; 53: 483-490.
16. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969; 46: 428-440.
17. Murata I, Takenaka K, Shinohara S, Suzuki T, Sasaki T, Yamamoto K. Diversity of myocardial involvement in systemic sclerosis: an 8-year study of 95 Japanese patients. Am Heart J. 1998; 135: 960-969.
18. Beranek JT. Pathogenesis of heart fibrosis in systemic sclerosis. Int J Cardiol. 2001; 80: 261-262.
19. Deswal A, Follansbee WP. Cardiac involvement in scleroderma. Rheum Dis Clin North Am. 1996; 22: 841-860.
20. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007; 117: 557-567.
21. Kahan A, Nitenberg A, Foult JM, et al. Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum. 1985; 28: 637-646.
22. Montisci R, Vacca A, Garau P, et al. Detection of early impairment of coronary flow reserve in patients with systemic sclerosis. Ann Rheum Dis. 2003; 62: 890-893.
23. Sulli A, Ghio M, Bezante GP, et al. Blunted coronary flow reserve in systemic sclerosis. Rheumatology (Oxford). 2004; 43: 505-509.
24. Alexander EL, Firestein GS, Weiss JL, et al. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med. 1986; 105: 661-668.
25. Long A, Duffy G, Bresnihan B. Reversible myocardial perfusion defects during cold challenge in scleroderma. Br J Rheumatol. 1986; 25: 158-161.
26. Kahan A, Devaux JY, Amor B, et al. Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma. Ann Rheum Dis. 1986; 45: 718-725.
27. Kahan A, Devaux JY, Amor B, et al. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med. 1986; 314: 1397-1402.
28. Kahan A, Devaux JY, Amor B, et al. Nicardipine improves myocardial perfusion in systemic sclerosis. J Rheumatol. 1988; 15: 1395-1400.
29. Kahan A, Devaux JY, Amor B, et al. The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis. Clin Pharmacol Ther. 1990; 47: 483-489.
30. Ishida R, Murata Y, Sawada Y, Nishioka K, Shibuya H. Thallium-201 myocardial SPET in patients with collagen disease. Nucl Med Commun. 2000; 21: 729-734.
31. Duboc D, Kahan A, Maziere B, et al. The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study. Arthritis Rheum. 1991; 34: 198-203.
32. Meune C, Allanore Y, Pascal O, et al. Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. Eur J Echocardiogr. 2005; 6: 351-357.
33. Vignaux O, Allanore Y, Meune C, et al. Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis. 2005; 64: 1268-1273.
34. Budev MM, Minai OA, Arroliga AC. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension. Drugs Today (Barc). 2004; 40: 225-234.
35. Fernandes F, Ramires FJ, Arteaga E, Ianni BM, Bonfá ES, Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail. 2003; 9: 311-317.
36. Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol. 1989; 28: 281-286.
37. Candell-Riera J, Armadans-Gil L, Simeón CP, et al. Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum. 1996; 39: 1138-1145.
38. Ellis WW, Baer AN, Robertson RM, Pincus T, Kronenberg MW. Left ventricular dysfunction induced by cold exposure in patients with systemic sclerosis. Am J Med. 1986; 80: 385-392.
39. Follansbee WP, Miller TR, Curtiss EI, et al. A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol. 1990; 17: 656-662.
40. Maione S, Cuomo G, Giunta A, et al. Echocardiographic alterations in systemic sclerosis: a longitudinal study. Semin Arthritis Rheum. 2005; 34: 721-727.
41. Janosik DL, Osborn TG, Moore TL, Shah DG, Kenney RG, Zuckner J. Heart disease in systemic sclerosis. Semin Arthritis Rheum. 1989; 19: 191-200.
42. Meune C, Avouac J, Wahbi K, et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum. 2008; 58: 1803-1809.
43. Toumanidis ST, Papamichael CM, Antoniades LG, et al. Cardiac involvement in collagen diseases. Eur Heart J. 1995; 16: 257-262.
44. de Groote P, Gressin V, Hachulla E, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis. 2008; 67: 31-36.
45. D'Andrea A, Stisi S, Bellissimo S, et al. Early impairment of myocardial function in systemic sclerosis: non-invasive assessment by Doppler myocardial and strain rate imaging. Eur J Echocardiogr. 2005; 6: 407-418.
46. Samsonov M, Nassonov E, Kostin S, et al. Serum neopterin-possible immunological marker of myocardial inflammation in patients with dilated heart muscle disease. Eur Heart J. 1991; 12 Suppl D: 151-153.
47. Carette S, Turcotte J, Mathon G. Severe myositis and myocarditis in progressive systemic sclerosis. J Rheumatol. 1985; 12: 997-999.
48. Clemson BS, Miller WR, Luck JC, Feriss JA. Acute myocarditis in fulminant systemic sclerosis. Chest. 1992; 101: 872-874.
49. Follansbee WP, Zerbe TR, Medsger TA. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J. 1993; 125: 194-203.
50. Kerr LD, Spiera H. Myocarditis as a complication in scleroderma patients with myositis. Clin Cardiol. 1993; 16: 895-899.
51. Plastiras SC, Kelekis N, Tzelepis GE. Magnetic resonance imaging for the detection of myocardial fibrosis in scleroderma. N Engl J Med. 2006; 354: 2194-2196.
52. Aguglia G, Sgreccia A, Bernardo ML, et al. Left ventricular diastolic function in systemic sclerosis. J Rheumatol. 2001; 28: 1563-1567.
53. Wranicz J, Zielińska M, Cygankiewicz I, Dziankowska-Bartkowiak B, Sysa-Jedrzejowska A. Early cardiovascular involvement in patients with systemic sclerosis (SSc). Med Sci Monit. 2002; 8: CR78-82.
54. Maione S, Valentini G, Giunta A, et al. Evaluation of cardiac structures and function in systemic sclerosis by Doppler echocardiography. Cardiology. 1991; 79: 165-171.
55. Armstrong GP, Whalley GA, Doughty RN, et al. Left ventricular function in scleroderma. Br J Rheumatol. 1996; 35: 983-988.
56. Lee SW, Choi EY, Jung SY, Choi ST, Lee SK, Park YB. E/É ratio is more sensitive than E/A ratio for detection of left ventricular diastolic dysfunction in patients with systemic sclerosis. Clin Exp Rheumatol. 2010; 28: S12-17.
57. Giunta A, Tirri E, Maione S, et al. Right ventricular diastolic abnormalities in systemic sclerosis. Relation to left ventricular involvement and pulmonary hypertension. Ann Rheum Dis. 2000; 59: 94-98.
58. Henein MY, Cailes J, O'Sullivan C, du Bois RM, Gibson DG. Abnormal ventricular long-axis function in systemic sclerosis. Chest. 1995; 108: 1533-1540.
59. Hsiao SH, Lee CY, Chang SM, Lin SK, Liu CP. Right heart function in scleroderma: insights from myocardial Doppler tissue imaging. J Am Soc Echocardiogr. 2006; 19: 507-514.
60. Lindqvist P, Caidahl K, Neuman-Andersen G, et al. Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study. Chest. 2005; 128: 755-763.
61. Meune C, Allanore Y, Devaux JY, et al. High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. J Rheumatol. 2004; 31: 1941-1945.
62. Vonk NA, Naeije R. Right ventricular function in scleroderma-related pulmonary hypertension. Rheumatology (Oxford). 2008; 47 Suppl 5: v42-v43.
63. Bewley AP, Cooper JP, Levell NJ, Walker JM, Dowd PM. Systemic sclerosis associated with right ventricular cardiomyopathy. Br J Dermatol. 1996; 134: 1141-1143.
64. Lee CY, Chang SM, Hsiao SH, Tseng JC, Lin SK, Liu CP. Right heart function and scleroderma: insights from tricuspid annular plane systolic excursion. Echocardiography. 2007; 24: 118-125.
65. Bezante GP, Rollando D, Sessarego M, et al. Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. J Rheumatol. 2007; 34: 2431-2437.
66. Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis. 2009; 68: 1878-1884.
67. Matias C, Isla LP, Vasconcelos M, et al. Speckle-trackingderived strain and strain-rate analysis: a technique for the evaluation of early alterations in right ventricle systolic function in patients with systemic sclerosis and normal pulmonary artery pressure. J Cardiovasc Med (Hagerstown). 2009; 10: 129-134.
68. Kepez A, Akdogan A, Sade LE, et al. Detection of subclinical cardiac involvement in systemic sclerosis by echocardiographic strain imaging. Echocardiography. 2008; 25: 191-197.
69. McWhorter JE, LeRoy EC. Pericardial disease in scleroderma (systemic sclerosis). Am J Med. 1974; 57: 566-575.
70. Sackner MA, Heinz ER, Steinberg AJ. The heart in scleroderma. Am J Cardiol. 1966; 17: 542-559.
71. Byers RJ, Marshall DA, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis. 1997; 56: 393-394.
72. Keskin G, Külah E, Turgay M, Kinikli G, Duman M, Tokgöz G. Pericardial tamponade and systemic sclerosis. Clin Exp Rheumatol. 1996; 14: 701-702.
73. Nabatian S, Kantola R, Sabri N, Broy S, Lakier JB. Recurrent pericardial effusion and pericardial tamponade in a patient with limited systemic sclerosis. Rheumatol Int. 2007; 27: 759-761.
74. Satoh M, Tokuhira M, Hama N, et al. Massive pericardial effusion in scleroderma: a review of five cases. Br J Rheumatol. 1995; 34: 564-567.
75. Bowman S, Paice E, Binder A. Death from unsuspected diverticular disease in patients taking corticosteroids for polymyalgia rheumatica or giant cell arteritis. Br J Rheumatol. 1991; 30: 159-160.
76. Allali F, Alami M, Doghmi N, Mohatane A, Benomar M, Hajjaj-Hassouni N. Scleroderma complicated with tamponade during pregnancy. Joint Bone Spine. 2005; 72: 341-343.
77. Miniati I, Guiducci S, Mecacci F, Mello G, Matucci-Cerinic M. Pregnancy in systemic sclerosis. Rheumatology (Oxford). 2008; 47 Suppl 3: iii16-iii18.
78. Plastiras SC, Papazefkos V, Pamboucas C, Sfikakis P, Toumanidis S. Scleroderma heart: pericardial effusion with echocardiographic signs of tamponade during pregnancy. Clin Exp Rheumatol. 2010; 28: 447-448.
79. Bulkley BH, Klacsmann PG, Hutchins GM. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J. 1978; 95: 563-569.
80. Beller GA. Diagnostic accuracy of thallium-201 myocardial perfusion imaging. Circulation. 1991; 84: I1-6.
81. Gaál J, Hegedüs I, Dévényi K, Czirják L. Myocardial gallium-67 citrate scintigraphy in patients with systemic sclerosis. Ann Rheum Dis. 1995; 54: 856-858.
82. Gurtner C, Werner RJ, Winten G, et al. Early diagnosis of cardiac involvement in systemic sclerosis by 123I-MIBG neurotransmitter scintigraphy. Nucl Med Commun. 1998; 19: 849-857.
83. Lin CC, Ding HJ, Chen YW, Wang JJ, Ho ST, Kao A. Usefulness of technetium-99m sestamibi myocardial perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or systemic sclerosis. Int J Cardiol. 2003; 92: 157-161.
84. Steen VD, Follansbee WP, Conte CG, Medsger TA. Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum. 1996; 39: 677-681.
85. Sulli A, Ghio M, Bezante GP, et al. Blunted coronary flow reserve in systemic sclerosis: a sign of cardiac involvement in asymptomatic patients. Ann Rheum Dis. 2004; 63: 210-211.
86. Akram MR, Handler CE, Williams M, et al. Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford). 2006; 45: 1395-1398.
87. Derk CT, Jimenez SA. Acute myocardial infarction in systemic sclerosis patients: a case series. Clin Rheumatol. 2007; 26: 965-968.
88. Khurma V, Meyer C, Park GS, et al. A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. Arthritis Rheum. 2008; 59: 591-597.
89. Follansbee WP, Curtiss EI, Rahko PS, et al. The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. Am J Med. 1985; 79: 183-192.
90. Kostis JB, Seibold JR, Turkevich D, et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med. 1988; 84: 1007-1015.
91. Rankin AC. Arrhythmias in systemic sclerosis and related disorders. Card Electrophysiol Rev. 2002; 6: 152-154.
92. Ferri C, Bernini L, Bongiorni MG, et al. Noninvasive evaluation of cardiac dysrhythmias, and their relationship with multisystemic symptoms, in progressive systemic sclerosis patients. Arthritis Rheum. 1985; 28: 1259-1266.
93. Roberts NK, Cabeen WR, Moss J, Clements PJ, Furst DE. The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. Ann Intern Med. 1981; 94: 38-40.
94. Ciftci O, Onat AM, Yavuz B, et al. Cardiac repolarization abnormalities and increased sympathetic activity in scleroderma. J Natl Med Assoc. 2007; 99: 232-237.
95. Cozzolino D, Naclerio C, Iengo R, D'Angelo S, Cuomo G, Valentini G. Cardiac autonomic dysfunction precedes the development of fibrosis in patients with systemic sclerosis. Rheumatology (Oxford). 2002; 41: 586-588.
96. James TN. De subitaneis mortibus. VIII. Coronary arteries and conduction system in scleroderma heart disease. Circulation. 1974; 50: 844-856.
97. Loperfido F, Fiorilli R, Santarelli P, Bellocci F, Zecchi P. Severe involvement of the conduction system in a patient with sclerodermal heart disease. An electrophysiological study. Acta Cardiol. 1982; 37: 31-38.
98. Roberts NK, Cabeen WR. Atrioventricular nodal function in progressive systemic sclerosis: electrophysiological and morphological findings. Br Heart J. 1980; 44: 529-533.
99. Morelli S, Sgreccia A, De Marzio P, et al. Noninvasive assessment of myocardial involvement in patients with systemic sclerosis: role of signal averaged electrocardiography. J Rheumatol. 1997; 24: 2358-2363.
100. Mizuno R, Fujimoto S, Nakano H, et al. Atrial conduction abnormalities in patients with systemic progressive sclerosis. Eur Heart J. 1997; 18: 1995-2001.
101. Rankin AC, Osswald S, McGovern BA, Ruskin JN, Garan H. Mechanism of sustained monomorphic ventricular tachycardia in systemic sclerosis. Am J Cardiol. 1999; 83: 633-636, A11.
102. Kaiser W, Faber TS, Findeis M. Automatic learning of rules. A practical example of using artificial intelligence to improve computer-based detection of myocardial infarction and left ventricular hypertrophy in the 12-lead ECG. J Electrocardiol. 1996; 29 Suppl: 17-20.
103. Generini S, Fiori G, Moggi Pignone A, Matucci Cerinic M, Cagnoni M. Systemic sclerosis. A clinical overview. Adv Exp Med Biol. 1999; 455: 73-83.
104. Allanore Y, Meune C, Vignaux O, Weber S, Legmann P, Kahan A. Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J Rheumatol. 2006; 33: 2464-2469.
105. Kobayashi H, Yokoe I, Hirano M, et al. Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis. J Rheumatol. 2009; 36: 106-112.
106. Mele D, Censi S, La Corte R, et al. Abnormalities of left ventricular function in asymptomatic patients with systemic sclerosis using Doppler measures of myocardial strain. J Am Soc Echocardiogr. 2008; 21: 1257-1264.
107. Parcharidis G. Cardiovascular magnetic resonance in Greece: ready for prime time? Hellenic J Cardiol. 2011; 52: 557-558.